Idecabtagene vicleucel extended PFS compared with standard regimens for adults with advanced multiple myeloma, according to topline data released by the agent’s manufacturer.
Idecabtagene vicleucel (Abecma; Bristol Myers Squibb, 2seventy bio) — also known as ide-cel — is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy.
The FDA approved the agent in March 2021 for adults with relapsed or refractory multiple myeloma who received at least four previous lines of therapy, including an immunomodulatory agent, a proteasome inhibitor and an
